$4.97
0.00%
Nasdaq, Wed, Jun 11 2025
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$4.97
+1.68 51.06% 1M
-2.86 36.54% 6M
-3.37 40.41% YTD
-14.78 74.83% 1Y
-812.24 99.39% 5Y
-2,405.49 99.79% 10Y
-343.43 98.57% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.00 0.00%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $48.67m
Enterprise Value $129.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.24
P/S ratio (TTM) P/S ratio 0.47
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 127.41%
Revenue (TTM) Revenue $103.95m
EBIT (operating result TTM) EBIT $-210.51m
Free Cash Flow (TTM) Free Cash Flow $-230.47m
Cash position $78.74m
EPS (TTM) EPS $-20.50
P/E forward negative
Short interest 2.89%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast bluebird bio, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast bluebird bio, Inc.:

Buy
100%

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
104 104
127% 127%
100%
- Direct Costs 76 76
35% 35%
73%
28 28
371% 371%
27%
- Selling and Administrative Expenses 152 152
13% 13%
146%
- Research and Development Expense 87 87
41% 41%
84%
-149 -149
48% 48%
-144%
- Depreciation and Amortization 61 61
43% 43%
59%
EBIT (Operating Income) EBIT -211 -211
36% 36%
-203%
Net Profit -200 -200
34% 34%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Neutral
Business Wire
10 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly...
Neutral
Business Wire
13 days ago
WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right per share,...
Neutral
Business Wire
16 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subj...
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Employees 248
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today